Jun. 12 at 11:21 AM
$INVA Innoviva announces zoliflodacin NDA granted Priority Review by FDA
Innoviva announced that the FDA has granted Priority Review for the New Drug Application for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older.
The FDA assigned a target action date of December 15 under the PDUFA. It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.
